已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis

医学 阿替唑单抗 肿瘤科 内科学 彭布罗利珠单抗 贝伐单抗 危险系数 肺癌 无容量 养生 化疗 人口 置信区间 免疫疗法 癌症 环境卫生
作者
Fu Wenfan,XU Man-man,Shi Xingyuan,Jiang Zeyong,Jian Zhao,Lu Dai
出处
期刊:Therapeutic Advances in Chronic Disease [SAGE Publishing]
卷期号:14 被引量:4
标识
DOI:10.1177/20406223231189224
摘要

Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be confirmed.To identify the best first-line immunotherapy regimen for overall advanced NSCLC patients and different subgroups.Systematic review and Bayesian network meta-analysis (NMA).We searched several databases to retrieve relevant literature. We performed Bayesian NMA for the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (tr-AEs) with a grade equal or more than 3 (grade ⩾ 3 tr-AEs). Subgroup analysis was conducted according to programed death ligand 1 (PD-L1) levels, histologic type, central nervous system (CNS) metastases and tobacco use history.For the PD-L1 non-selective patients, sintilimab plus chemotherapy (sinti-chemo) provided the best OS [hazard ratio (HR) = 0.59, 95% confidence interval (CI):0.42-0.83]. Nivolumab plus bevacizumab plus chemotherapy (nivo-bev-chemo) was comparable to atezolizumab plus bevacizumab plus chemotherapy (atezo-bev-chemo) in prolonging PFS (HR = 0.99, 95% CI: 0.51-1.91). Atezo-bev-chemo remarkably elevated the ORR than chemotherapy (OR = 3.13, 95% CI: 1.51-6.59). Subgroup analysis showed pembrolizumab plus chemotherapy (pembro-chemo) ranked first in OS in subgroups of PD-L1 < 1%, non-squamous, no CNS metastases, with or without smoking history, and ranked second in OS in subgroups of PD-L1 ⩾ 1% and PD-L1 1-49%. Cemiplimab and sugemalimab plus chemotherapy ranked first in OS and PFS for squamous subgroup, respectively. For patients with CNS metastases, nivolumab plus ipilimumab plus chemotherapy (nivo-ipili-chemo) and camrelizumab plus chemotherapy provided the best OS and PFS, respectively.Sinti-chemo and nivo-bev-chemo were two effective first-line regimens ranked first in OS and PFS for overall patients, respectively. Pembro-chemo was favorable for patients in subgroups of PD-L1 < 1%, PD-L1 ⩾ 1%, PD-L1 1-49%, non-squamous, no CNS metastases, with or without smoking history. Addition of bevacizumab consistently provided with favorable PFS results in patients of all PD-L1 levels. Cemiplimab was the best option in squamous subgroup and nivo-ipili-chemo in CNS metastases subgroup due to their advantages in OS.First-line PD-1/PD-L1 inhibitors for advanced NSCLC patients lacking driver gene mutations Patients with advance non-small cell lung cancer (NSCLC) lacking driver gene mutations are a group of heterogeneous people. Although numerous therapeutic regimens were developed, the optimal choice for advanced NSCLC patients and specific subgroups is yet to be identified.We conducted a Bayesian network meta-analysis with the currently available data, and performed subgroup analyses according to programed death ligand 1 (PD-L1) levels, histologic type, CNS metastases and tobacco use history.Our key findings were as follows: (1) in non-selective PD-L1 groups, sinti-chemo and pembro-chemo provided the best OS outcome; nivo-bev-chemo and atezo-bev-chemo resulted in the most prolonged PFS; atezo-bev-chemo and pembro-chemo yielded significantly improved ORR; (2) pembro-chemo was favorable for patients in subgroups of PD-L1 < 1%, PD-L1 ⩾ 1%, PD-L1 1–49%, non-squamous, no CNS metastases, with or without smoking history; (3) immunochemotherapies involving anti-PD-1 agents generally exhibited potential advantages over those with anti-PD-L1 drugs; (4) addition of anti-VEGF drugs to immunochemotherapies consistently provided with favorable PFS results in advanced NSCLC patients with or without PD-L1 selection; (5) in patients with squamous NSCLC, cemiplimab and suge-chemo were the optimal drugs for improving OS and PFS, respectively; in patients with non-squamous NSCLC, pembro-chemo provided the best OS, while nivo-bev-chemo, atezo-bev-chemo, sinti-chemo, and pembro-chemo showed comparable advantages in improving PFS; (6) for patients with CNS metastases, nivo-ipili-chemo and camre-chemo provided the best OS and PFS, respectively.Our findings provide evidence for a more precise selection of first-line immunotherapy regimen for advanced NSCLC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被聪明紫山采纳,获得10
1秒前
Shaw完成签到,获得积分10
1秒前
MingWang发布了新的文献求助10
1秒前
李健的应助被ZZC采纳,获得10
2秒前
科研通AI6.4的应助被活着采纳,获得10
2秒前
2秒前
zcz发布了新的文献求助10
3秒前
4秒前
大只仙仙完成签到,获得积分10
7秒前
7秒前
花生了树发布了新的文献求助10
7秒前
8秒前
小怡完成签到 ,获得积分10
8秒前
Yeee1226发布了新的文献求助10
9秒前
syvshc的应助被MingWang采纳,获得10
10秒前
zcaw发布了新的文献求助10
10秒前
13秒前
13秒前
搜集达人的应助被zcaw采纳,获得10
13秒前
bkagyin的应助被沐染采纳,获得10
14秒前
14秒前
阳阳来袭完成签到,获得积分10
16秒前
ou发布了新的文献求助10
18秒前
18秒前
JamesPei的应助被科研通管家采纳,获得10
18秒前
完美世界的应助被科研通管家采纳,获得10
18秒前
zy发布了新的文献求助10
18秒前
无极微光的应助被科研通管家采纳,获得20
18秒前
VDC的应助被科研通管家采纳,获得30
18秒前
18秒前
18秒前
wanci的应助被科研通管家采纳,获得10
19秒前
19秒前
19秒前
Lucas的应助被科研通管家采纳,获得20
19秒前
李爱国的应助被科研通管家采纳,获得10
19秒前
隐形曼青的应助被科研通管家采纳,获得10
19秒前
19秒前
19秒前
csq完成签到 ,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194529
求助须知:如何正确求助?哪些是违规求助? 9580304
关于积分的说明 21870538
捐赠科研通 7794101
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484393